Pfizer faces crucial panel vote on blockbuster hopeful tofacitinib

Wounded by plummeting Lipitor sales, Pfizer ($PFE) has high hopes for one of the gems of the pharma giant's pipeline, tofacitinib, and next week FDA advisers will take their turn dissecting the upside…
Read the full story: News